A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

The brands Rybelsus and Ozempic are currently FDA-approved for diabetes management, and Wegovy is used to assist with weight loss ... in the semaglutide group had better outcomes from non-invasive ...

GLP-1 agonists, medications commonly used for weight loss and type 2 diabetes, may also help reduce alcohol intake — an ...

Trials have confirmed the efficacy of GLP-1 RAs in achieving clinically sustained weight loss in people with obesity without diabetes.

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular ...

In the first direct comparison study involving individuals with obesity, tirzepatide demonstrated approximately 50% greater ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...

In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

Discover how semaglutide reduces heart attack and stroke risk by 20% in overweight individuals, with benefits appearing ...